Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Development of GPC3-Specific Chimeric Antigen Receptor-Engineered Natural Killer Cells for the Treatment of Hepatocellular Carcinoma.

Molecular therapy : the journal of the American Society of Gene Therapy - 7 Feb 2018

Yu Min, Luo Hong, Fan Mingliang, Wu Xiuqi, Shi Bizhi, Di Shengmeng, Liu Ying, Pan Zeyan, Jiang Hua, Li Zonghai

Abstract excerpt

Chimeric antigen receptor (CAR)-modified natural killer (NK) cells represent a promising immunotherapeutic modality for cancer treatment. However, their potential utilities have not been explored in hepatocellular carcinoma (HCC). Glypian-3 (GPC3) is a rational immunotherapeutic target for HCC. In this study, we developed GPC3-specific NK cells and explored their potential in the treatment of HCC....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Gene Order
Share to Glypicans

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Heterografts

Share to Immunotherapy, Adoptive

Share to Killer Cells, Natural

Share to Lentivirus

Share to Receptors, Chimeric Antigen

Share to Transduction, Genetic

Source

Open in PubMed Open full text

Identifiers

PMID: 29339014
DOI: 10.1016/j.ymthe.2017.12.012
PMCID: PMC5835122

Genes

GPC3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Development of GPC3-Specific Chimeric Antigen Receptor-Engineered Natural Killer Cells for the Treatment of Hepatocellular Carcinoma.PMID 29339014Read ↗

Exploring Glypican-3 Targeted CAR-NK Treatment and Potential Therapy Resistance in Hepatocellular CarcinomaSemantic proximity Read ↗

Enhanced specific antitumor immunity of dendritic cells transduced with the glypican 3 gene and co-cultured with cytokine-induced killer cells against hepatocellular carcinoma cells.Semantic proximity Read ↗

Chimeric antigen receptor-natural killer cell therapy: a new force in intrinsic immunotherapy for cancer treatmentSemantic proximity Read ↗

Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinomaSemantic proximity Read ↗

Novel NK cell-like phenotype expressing CCR5 and its ligands elicits tumor-specific acquired immunity to carcinomatous peritonitis via host NK-derived IFN-γ.Semantic proximity Read ↗

Precision immunotherapy for cholangiocarcinoma: Pioneering the use of human-derived anti-cMET single chain variable fragment in anti-cMET chimeric antigen receptor (CAR) NK cellsSemantic proximity Read ↗

Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor.Semantic proximity Read ↗

The phenotype of ex vivo generated cytokine-induced killer cells is associated with overall survival in patients with cancer.Semantic proximity Read ↗

NK cells specifically TCR-dressed to kill cancer cellsSemantic proximity Read ↗

CAR-NK cells with dual targeting of PD-L1 and MICA/B in human lung cancer H1299 cell tumor modelSemantic proximity Read ↗

BOXR1030, an anti-GPC3 CAR with exogenous GOT2 expression, shows enhanced T cell metabolism and improved antitumor activitySemantic proximity Read ↗

Novel low-avidity glypican-3 specific CARTs resist exhaustion and mediate durable antitumor effects against hepatocellular carcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.